Another study from my group was published in the Lancet Rheumatology showing efficacy and safety of the IL-1 blocking agent anakinra and superiority of this treatment to IL-6 blockers (such as tocilizumab and sarilumab) in severe COVID-19 pneumonia. We have been the...

read more